During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

In recent years, cancer immunotherapy has made remarkable achievements. Immune
checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the …

Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also
predispose patients to immune-related adverse events like immune-mediated colitis (IMC) …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet quality of life
and continuation of therapy can be constrained by immune-related adverse events (irAEs) …

Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still
constrained by lack of response and toxicity. Biomarkers of response may facilitate drug …

Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have improved the field of
cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular …

Abstract Purpose of Review The use of immune checkpoint inhibitors (ICIs) for oncologic
indications is associated with immune-related adverse events (irAEs). Patients with pre …

Non-melanoma skin cancers (NMSCs) are the most common form of skin cancer worldwide.
The global incidence of cutaneous squamous cell carcinoma (CSCC) is rising, with an …

Background: This systematic review and network meta-analysis aimed to provide a complete
hepatotoxicity profile, hepatotoxicity spectrum, and safety ranking of immune checkpoint …

Simple Summary The effectiveness and safety of immune checkpoint inhibitors in the
treatment of patients with advanced cutaneous squamous cell carcinoma were evaluated in …